By Doug Dayhoff, CFO, INCOG BioPharma
When entering a partnership with a contract development and manufacturing organization (CDMO), it is important to understand the different types of manufacturing systems used to produce clinical drug product. In the event of early-phase success, a CDMO’s equipment and facility design can either accelerate or handicap your drug’s future potential and value.
An early-stage manufacturing strategy that maximizes future optionality, reduces time between milestones, and minimizes future risks and workload certainly has material financial value.
This article highlights the importance of scalability and flexibility in the choice of an early-stage manufacturing strategy and how that decision impacts financial outcomes for a drug development program.